Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab in Active Non-radiographic Axial Spondyloarthritis
NCT02696031Phase 3Completed
- Sponsor
- Novartis
- Start
- Apr 2016
- Primary completion
- Jul 2019
- Modality
- Monoclonal Antibodies
- Countries
- 24
01
Overview
Phase 3, randomised, double-blind trial of secukinumab in non-radiographic axial spondyloarthritis (nr-axSpA) (6 arms), sponsored by Novartis. Primary endpoint: Assessment of SpondyloArthritis International Society 40 Response in TNF Naive Participants at 16 weeks. Started Apr 2016; status: completed.
02
Drugs
secukinumab
03
Conditions
non-radiographic axial spondyloarthritis (nr-axSpA)
Beyond the preview
Go deeper on NCT02696031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02696031.